Hossein Khanahmad

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 11

Top Topics

Breast Cancer Cells

Structure Activity Relationship

Transcranial Direct Current Stimulation

Major Depressive Disorder

Top Venues

Future medicinal chemistry

Acta parasitologica

Metabolic brain disease

Molecular biology reports

This page only lists publications with an associated author ORCID identifier.

Publications

Vajihe Saedi Marghmaleki, Maryam Radahmadi, Hojjatallah Alaei, Hossein Khanahmad
Effects of prolonged escitalopram administration on long-term potentiation within the hippocampal CA1 area in rats under predictable and unpredictable chronic mild stress. Metabolic brain disease (2024)
Ali Mehri, Mahboubeh Mardanshahi, Hajar Sirous, Hossein Khanahmad, Mahboubeh Rostami
Pyrimido[4,5-b]indole derivatives bearing 1,2,4-oxadiazole moiety as MDM2 inhibitor candidates in cancer treatment. Future medicinal chemistry 15 (6) (2023)
Ali Mehri, Mahboubeh Mardanshahi, Hajar Sirous, Hossein Khanahmad, Mahboubeh Rostami
Pyrimido[4,5-b]indole derivatives bearing 1,2,4-oxadiazole moiety as MDM2 inhibitor candidates in cancer treatment. Future medicinal chemistry (2023)
Ali Mehri, Mahboubeh Mardanshahi, Hajar Sirous, Hossein Khanahmad, Mahboubeh Rostami
Pyrimido[4,5-b]indole derivatives bearing 1,2,4-oxadiazole moiety as MDM2 inhibitor candidates in cancer treatment. Future medicinal chemistry 15 (6) (2023)
Ali Mehri, Mahboubeh Mardanshahi, Hajar Sirous, Hossein Khanahmad, Mahboubeh Rostami
Pyrimido[4,5-b]indole derivatives bearing 1,2,4-oxadiazole moiety as MDM2 inhibitor candidates in cancer treatment. Future medicinal chemistry 15 (6) (2023)
Ali Mehri, Mahboubeh Mardanshahi, Hajar Sirous, Hossein Khanahmad, Mahboubeh Rostami
Pyrimido[4,5-b]indole derivatives bearing 1,2,4-oxadiazole moiety as MDM2 inhibitor candidates in cancer treatment. Future medicinal chemistry (2023)
Ali Mehri, Mahboubeh Mardanshahi, Hajar Sirous, Hossein Khanahmad, Mahboubeh Rostami
Pyrimido[4,5-b]indole derivatives bearing 1,2,4-oxadiazole moiety as MDM2 inhibitor candidates in cancer treatment. Future medicinal chemistry 15 (6) (2023)
Ali Mehri, Mahboubeh Mardanshahi, Hajar Sirous, Hossein Khanahmad, Mahboubeh Rostami
Pyrimido[4,5-b]indole derivatives bearing 1,2,4-oxadiazole moiety as MDM2 inhibitor candidates in cancer treatment. Future medicinal chemistry 15 (6) (2023)
Mahsa Esmaeilifallah, Hossein Khanahmad, Zahra Ghayour, Sedigheh Saberi, Reza Kalantari, Seyed Hossein Hejazi
Evaluation of the antileishmanial effect of polyclonal antibodies and cationic antimicrobial peptides. Pathogens and global health (2022)
Mina Mirian, Shirin Kouhpayeh, Laleh Shariati, Maryam Boshtam, Ilnaz Rahimmanesh, Leila Darzi, Razieh Taghizadeh, Ali Jahanian-Najafabadi, Hossein Khanahmad
Generation of HBsAg DNA aptamer using modified cell-based SELEX strategy. Molecular biology reports 48 (1) (2021)
Seyedeh Noushin Zahedi, Seyed Hossein Hejazi, Maryam Boshtam, Farahnaz Amini, Hossein Fazeli, Mahdieh Sarmadi, Mahsa Rahimi, Hossein Khanahmad
Recombinant C-Reactive Protein: A Potential Candidate for the Treatment of Cutaneous Leishmaniasis of BALB/c Mice Caused by Leishmania major. Acta parasitologica 66 (1) (2020)